SG&A at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s SG&A?
- Xeris Biopharma Holdings, Inc. (XERS) reported SG&A of $53.14M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s SG&A changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s SG&A increased by 20.7% year-over-year, from $44.02M to $53.14M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s SG&A has grown at a 9.7% compound annual growth rate (CAGR), from $125.72M to $182.37M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.